Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

International Study Highlights Importance of Inhaler Technique on Asthma Patient Outcomes


News provided by

Observational and Pragmatic Research Institute, Respiratory Effectiveness Group and Optimum Patient Care

13 Mar, 2017, 00:01 GMT

Share this article

Share toX

Share this article

Share toX

CAMBRIDGE, England, March 13, 2017 /PRNewswire/ --

For European Medical and Trade Media Only

  • International CRITIKAL Study[1] is one of the largest to investigate inhaler technique and the first to analyse the direct associations between specific inhaler errors and asthma outcomes 
  • Critical errors were identified that were frequent, made by over 30% of patients in some cases, and were associated with worse asthma outcomes[1]
  • Study highlights how primary and secondary care asthma management could target inhaler training to reduce these critical errors and improve patient outomes[1]

A new study published today in the Journal of Allergy and Clinical Immunology: In Practice highlights important findings from the international CRITIKAL study[1] (CRITical Inhaler mistaKes and Asthma controL). CRITIKAL is the first study to assess the associations between specific inhaler errors and poorer asthma outcomes in patients receiving a fixed-dose combination treatment with inhaled corticosteroids and long-acting beta agonist (ICS/LABA) via dry-powder inhalers (DPIs) and metered-dose inhalers (MDIs). The CRITIKAL analysis used data from 3,660 patients included in the iHARP asthma review service[2] (initiative Helping Asthma in Real-life Patients) - a multi-centre, cross-sectional review of over 5,000 adults with asthma delivered by Optimum Patient Care (http://www.optimumpatientcare.org). This was an investigator initiated trial with data analysis undertaken by the Observational and Pragmatic Research Institute in collaboration with members of the Respiratory Effectiveness Group and part-funded by a grant from Mundipharma Research Limited.

"When managing asthma, our aim is to reduce the risk of exacerbations and control patients' symptoms. If patients are not aware how to use their inhaler devices correctly, the effectiveness of their treatment is diminished, which can lead to poorly controlled asthma impacting the patient's quality of life and can also lead to unnecessary costs to healthcare systems.  The real-world CRITIKAL study identified the specific critical inhaler errors that are frequent and impact asthma outcomes. This study could help routine patient management by targeting training to reduce these critical errors with the aim of improving overall patient outcomes," said Professor David Price, Chair of Primary Care Respiratory Medicine at the University of Aberdeen, Aberdeen, UK, Director of the Observational and Pragmatic Research Institute and ex-Chairman of the Respiratory Effectiveness Group.

The results of the CRITIKAL analysis showed that certain errors were frequent, made by over 30% of patients in some cases, and associated with poor asthma control. Some errors were device-specific whereas others were generic across devices.[1]

Previous studies have shown that poor or improper inhaler technique in asthma is associated with reduced control[3],[4] and an increase in hospital visits.[3] However, these results provide crucial insights into which specific inhaler errors are linked to poor asthma outcomes (including increased likelihood of having uncontrolled symptoms and increased exacerbation rate). The study highlights that choosing the right inhaler type for each patient along with training by primary and secondary healthcare management teams is needed to help reduce the number of critical inhaler errors and ultimately improve patient health.[1]

Notes to editors: 

About Observational and Pragmatic Research Institute (OPRI) 

OPRI aims to improve disease management and patient outcomes by undertaking the highest quality observational and pragmatic clinical research in real-life factors that influence outcomes and real life effectiveness both in terms of disease management and pharmacological interventions. By collaborating with clinical, academic and industry partners, OPRI drives a vision for inclusion of real-life research into all aspects of medical research. Professor David Price has been a world leader in respiratory real-life research for over 20 years. http://www.opri.sg.

About Respiratory Effectiveness Group (REG) 

The Respiratory Effectiveness Group (http://www.effectivenessevaluation.org) is a not-for-profit initiative established by international experts in real-life and comparative effectiveness research in respiratory medicine. The Group sets quality standards in the field of real-life research and improves understanding of the optimum role of real-life data to inform meaningful clinical practice guidelines, drug licensing and post-marketing surveillance processes and improved patient care.

About Mundipharma Research 

Mundipharma Research comprises of two independent associated companies, Mundipharma Research Limited in Cambridge England and Mundipharma Research GmbH of Limburg, Germany who are wholly dedicated to the research and development of innovative medications in three main therapeutic areas - pain, oncology and respiratory diseases.

Mundipharma Research works on behalf of a network of independent associated companies and also in collaboration with other pharmaceutical companies to bring medications to an international market. For more information, visit the company's website at  http://www.mundipharma-rd.eu

About Optimum Patient Care 

Optimum Patient Care is a social enterprise providing clinical reviews and observational research support services to over 600 GP practices across the UK. OPC has established one of the largest healthcare databases in the world, called the Optimum Patient Care Research Database (OPCRD) which holds over 3.4 million anonymised electronic health records linked to information on patient reported data from 50,000 patients with asthma and COPD. OPC delivered and is the guardian of the global iHARP database. OPC's mission is to collaborate with clinical, academic and industry partners across the globe, to drive its vision for the collection and inclusion of real-life data into medical research and clinical practice. http://www.optimumpatientcare.org.

About Asthma   

Asthma is a chronic inflammatory disorder of the airways which leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Patients with poorly managed asthma are at an increased risk of exacerbations, hospitalisation and death. Poorly managed asthma can also have a huge impact on a person's quality of life and day-to-day activities.[5]  

About CRITIKAL 

CRITical Inhaler mistaKes and Asthma control (CRITIKAL) study is a multi-national, cross-sectional, observational analysis investigating direct relationships between specific inhaler errors in DPI and MPI inhalers and asthma outcomes, and determined the critical errors for each inhaler type. It was an investigator initiated trial (IIT) conducted by the Respiratory Effectiveness Group. The analysis used data from the Helping Asthma in Real-life Patients (iHARP) asthma review service - a multi-centre cross-sectional review of adults with asthma in Australia and seven European countries (United Kingdom, Italy, Spain, the Netherlands, France, Norway and Sweden). The review took place between 2011 and 2014 and captured data from over 5,000 patients on demographics, asthma symptoms and inhaler errors observed by purposefully trained healthcare professionals.

References:                                                      

1. D.Price et al. "Inhaler errors in the CRITIKAL Study: type, frequency and association with asthma outcomes". Journal of Allergy and Clinical Immunology: In Practice. 2017 DOI: http://dx.doi.org/10.1016/j.jaip.2017.01.004

2. iHARP database. http://iharp.org/ [http://iharp.org ] Last accessed 6 March 2017

3. Al-Jahdali H, Ahmed A, Al-Harbi A, Khan M, Baharoon S, Bin Salih S, et al. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol. 2013;9(1):8.

4. Baddar S, Jayakrishnan B, Al-Rawas OA. Asthma control: importance of compliance and inhaler technique assessments. J Asthma. 2014;51(4):429-34.

5. Chen H et al. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease

J Allergy Clin Immunol. [https://www.ncbi.nlm.nih.gov/pubmed/17561244 ] 2007;120(2):396-402

Job code: MINT/RESP-17002
Date of preparation: March 2017

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.